Study Title

novartis

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent

Study Details

Description:

This study aims to establish the recommended dose of [177Lu]Lu-DOTA-TATE in combination with the standard of care or as single agent in three different groups of participants with Glioblastoma (a brain cancer).

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided




© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468